Page last updated: 2024-11-06

4-carboxybiphenyl ether

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-carboxybiphenyl ether: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-phenoxybenzoic acid : A phenoxybenzoic acid in which the phenoxy group is para to the carboxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID75182
CHEMBL ID107518
CHEBI ID72632
SCHEMBL ID200428
MeSH IDM0181067

Synonyms (54)

Synonym
AC-7354
4-phoc6h4cooh
4-phoc6h4co2h
p-carboxydiphenyl ether
unii-k7yp1jl5bz
k7yp1jl5bz ,
nsc246039
4-phenoxybenzoic acid
2215-77-2
nsc-246039
diphenyl ether 4-carboxylic acid
p-phenoxybenzoic acid
benzoic acid, p-phenoxy-
benzoic acid, 4-phenoxy-
inchi=1/c13h10o3/c14-13(15)10-6-8-12(9-7-10)16-11-4-2-1-3-5-11/h1-9h,(h,14,15
4-carboxybiphenyl ether
nsc 246039
einecs 218-682-5
TIMTEC1_000711
CBDIVE_013558
OPREA1_785025
4-phenoxybenzoic acid, 97%
NCGC00175201-01
HMS1536A07
AKOS000118807
BRD-K51068875-001-01-0
4-phenoxy-benzoic acid
4-phenoxy benzoic acid
CHEMBL107518 ,
chebi:72632 ,
P1256
bdbm50060966
AE-641/01666029
4-carboxydiphenyl ether
BP-12516
FT-0619369
AR1892
4-(phenyloxy)benzoic acid
SCHEMBL200428
mfcd00002539
SY005874
DTXSID6062258
PS-7961
F2191-0037
CS-D1189
J-014558
Q27140032
p-phenoxybenzoic acid;benzoic acid, 4-phenoxy-;diphenyl ether 4-carboxylic acid
BCP27317
EN300-18382
jo4 ,
AMY8794
HY-78854
Z57127881
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenoxybenzoic acidAn aromatic ether that is diphenyl ether in which one of the hydrogens is replaced by a carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-lactamase Klebsiella pneumoniaeKd660.00000.85000.85000.8500AID1320842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1320843Inhibition of native signal containing Klebsiella pneumoniae OXA-48 using nitrocefin substrate pre-incubated for 5 mins before substrate addition2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening.
AID660664Agonist activity at PPARalpha2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Synthesis and SAR of 1,3-thiazolyl thiophene and pyridine derivatives as potent, orally active and S1P₃-sparing S1P₁ agonists.
AID1320842Binding affinity to native signal deficient and TEV cleavage site containing His-tagged Klebsiella pneumoniae OXA-48 expressed in Escherichia coli assessed as dissociation constant by SPR assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening.
AID84392Dissociation constant after binding to human papillomavirus E2 DNA-binding domain (DBD) by observing the changes in [15N]-HSQC spectra.1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (18.75)18.2507
2000's3 (18.75)29.6817
2010's6 (37.50)24.3611
2020's4 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.01 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.84 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]